Discovery of antiviral inhibitors of Ebola virus replication

发现埃博拉病毒复制的抗病毒抑制剂

• 批准号: 10216627
• 负责人: Glen Andrew Coburn
• 金额: $ 30万
• 依托单位: VENATORX PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-15 至 2022-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10216627
• 关键词: Affect; Affinity Chromatography; Africa; Antiviral Agents; Area; Automobile Driving; Binding; Biological Assay; Centers for Disease Control and Prevention (U.S.); Cessation of life; Collaborations; Congo; Containment; Country; Development; Disease Outbreaks; Dose; Drug Kinetics; Ebola; Ebola Hemorrhagic Fever; Ebola virus; Ectopic Expression; Epidemic; Evaluation; Genetic Transcription; Genome; Geography; Goals; Health; Health Personnel; Human; Individual; Infection; Infrastructure; Laboratories; Lead; Letters; Libraries; Luciferases; Maps; Mutation; Nucleocapsid; Oral; Pathogenicity; Persons; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; Play; Predisposition; Prevention; Property; Proteins; RNA; RNA replication; Reporter; Resistance; Role; Security; Series; Signal Transduction; Small Business Innovation Research Grant; Socioeconomic Factors; Source; Structure; Structure-Activity Relationship; System; Time; Translations; Variant; Viral; Virus; Virus Diseases; Virus Replication; authority; biosecurity; candidate selection; cytotoxicity; experience; high throughput screening; improved; indexing; inhibitor/antagonist; innovation; lead optimization; lead series; medical countermeasure; mortality; new technology; novel; novel therapeutics; pathogen; prevent; programs; response; reverse genetics; small molecule; targeted agent; transmission process; viral transmission

Ebola viruses (EBOV) cause severe illnesses in humans with a high rate of mortality that approaches 90%. Novel therapies with potent and selective activity against EBOV are urgently needed for the prevention and treatment of Ebola virus disease (EVD). We propose to execute an innovative high throughput screening campaign using a unique reverse genetics system. This screen is expected to yield new inhibitors targeting EBOV replication that will serve as starting points for medicinal chemistry hit-to-lead efforts. If successful, we will deliver one or more new lead series targeting EBOV infection.

埃博拉病毒 (EBOV) 会导致人类严重疾病，死亡率高达 90%。 迫切需要针对埃博拉病毒具有有效和选择性活性的新疗法来预防和治疗埃博拉病毒。 埃博拉病毒病（EVD）的治疗。我们建议执行创新的高通量筛选 使用独特的反向遗传学系统的活动。该筛选有望产生新的抑制剂 EBOV 复制将作为药物化学先导化合物工作的起点。如果成功的话，我们 将提供一个或多个针对埃博拉病毒感染的新先导系列。